Pan Pacific Lymphoma Conference | Conference

Dr. Ansell on Incorporating Immunotherapies Beyond CAR T-Cell Therapy in NHL

August 11th 2021

Stephen M. Ansell, MD, PhD, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

Lead Investigator Highlights ECHELON-1 Lymphoma Data From North American Subgroup

September 27th 2018

Radhakrishnan Ramchandren, MD, discusses the treatment landscape in Hodgkin and T-cell lymphoma and the results of the North American subgroup analysis of the ECHELON-1 trial.

Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin Lymphoma

September 15th 2018

Radhakrishnan Ramchandren MD, associate professor, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, discusses the North American results of the ECHELON-1 study in Hodgkin lymphoma.

Dr. Lonial Discusses Emerging Agents in Relapsed/Refractory Myeloma

July 20th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.

Dr. Smith Discusses Brentuximab Vedotin in CTCL

July 20th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.

Ansell Discusses Combination Potential in Hodgkin Lymphoma

July 20th 2018

Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.

Lonial Lays Out Optimal Sequence Strategies for Relapsed/Refractory Myeloma

July 20th 2018

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

US Versus European Opinions on Upfront Therapy in Hodgkin Lymphoma

July 20th 2018

United States’ versus European perspectives on bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma, along with the value of interim positron emission tomography, were discussed at the 2018 Pan Pacific Lymphoma Conference.

Dr. Roschewski Discusses DA-EPOCH-R in Burkitt Lymphoma

July 20th 2018

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

Dr. Kahl Discusses Polatuzumab Vedotin in Lymphoma

July 20th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.

Bleomycin Linked to High Rate of Pulmonary Disorders among Patients with Hodgkin Lymphoma

July 20th 2018

A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.

Treatment Options for CD30-Positive PTCL Subtypes

July 19th 2018

Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.

The Future of Myeloma Induction May Be Quadruplets

July 19th 2018

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

Dr. Maloney Discusses Updates With CAR T-Cell Therapy in NHL

July 18th 2018

David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses updates with CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Vose Discusses the Importance of Genomic Analysis in NHL

July 18th 2018

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma

July 18th 2018

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

Kahl Shares Antibody-Drug Conjugate Updates in Lymphoma

July 18th 2018

With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.

Key Characteristics Emerging for CAR T Cell Success

July 18th 2018

An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.